Goldman Sachs Group Inc Pacira Bio Sciences, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,104,796 shares of PCRX stock, worth $26.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,104,796
Previous 1,104,796
-0.0%
Holding current value
$26.8 Million
Previous $27.5 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding PCRX
# of Institutions
254Shares Held
51.1MCall Options Held
157KPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$194 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.24MShares$127 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$54.9 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.24MShares$54.3 Million0.09% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.05MShares$49.7 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.11B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...